Clinical Trial

A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This trial adopts a multicenter, open label, positive drug parallel controlled clinical trial design, with a planned enrollment of approximately 105 participants in the MF trial. Successful trial participants were selected and assigned to either the experimental group or the control group in a 2:1 stratified manner, with the stratification factor being the Dynamic International Prognostic Scoring System (DIPSS) prognostic grading criteria. Continuously take the test drug/control drug until it meets the withdrawal criteria.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-19; most recent amendment 2026-03-02.
Status change: Not Yet Recruiting → Recruiting 2026-03-02
Trial Details
NCT Number NCT07317700
Lead Sponsor Chengdu Zenitar Biomedical Technology Co., Ltd
Conditions MF
Enrollment 105 participants
Start Date 2026-02-13
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-13